Literature DB >> 29941608

How to eliminate MYCN-positive hepatic cancer stem cells to prevent the recurrence?

Go J Yoshida1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29941608      PMCID： PMC6048488          DOI： 10.1073/pnas.1808092115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

1.  ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.

Authors:  Ping Ren; Ming Yue; Daibiao Xiao; Ruijuan Xiu; Lei Gan; Hudan Liu; Guoliang Qing
Journal:  J Pathol       Date:  2014-10-06       Impact factor: 7.996

Review 2.  The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.

Authors:  Himisha Beltran
Journal:  Mol Cancer Res       Date:  2014-03-03       Impact factor: 5.852

Review 3.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

Review 4.  Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid.

Authors:  C P Redfern; P E Lovat; A J Malcolm; A D Pearson
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

Review 5.  The increasing complexity of the cancer stem cell paradigm.

Authors:  Jeffrey M Rosen; Craig T Jordan
Journal:  Science       Date:  2009-06-26       Impact factor: 47.728

6.  E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas.

Authors:  Christoph Kramps; Verena Strieder; Alexandra Sapetschnig; Guntram Suske; Werner Lutz
Journal:  J Biol Chem       Date:  2003-11-26       Impact factor: 5.157

7.  NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

Authors:  Yusuke Suenaga; S M Rafiqul Islam; Jennifer Alagu; Yoshiki Kaneko; Mamoru Kato; Yukichi Tanaka; Hidetada Kawana; Shamim Hossain; Daisuke Matsumoto; Mami Yamamoto; Wataru Shoji; Makiko Itami; Tatsuhiro Shibata; Yohko Nakamura; Miki Ohira; Seiki Haraguchi; Atsushi Takatori; Akira Nakagawara
Journal:  PLoS Genet       Date:  2014-01-02       Impact factor: 5.917

Review 8.  The evolving concept of liver cancer stem cells.

Authors:  Kouki Nio; Taro Yamashita; Shuichi Kaneko
Journal:  Mol Cancer       Date:  2017-01-30       Impact factor: 27.401

9.  Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid.

Authors:  Xian-Yang Qin; Harukazu Suzuki; Masao Honda; Hikari Okada; Shuichi Kaneko; Ikuyo Inoue; Etsuko Ebisui; Kosuke Hashimoto; Piero Carninci; Keita Kanki; Hideki Tatsukawa; Naoto Ishibashi; Takahiro Masaki; Tomokazu Matsuura; Hiroyuki Kagechika; Kan Toriguchi; Etsuro Hatano; Yohei Shirakami; Goshi Shiota; Masahito Shimizu; Hisataka Moriwaki; Soichi Kojima
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

Review 10.  Potential role of the N-MYC downstream-regulated gene family in reprogramming cancer metabolism under hypoxia.

Authors:  Ga Young Lee; Yang-Sook Chun; Hyun-Woo Shin; Jong-Wan Park
Journal:  Oncotarget       Date:  2016-08-30
  10 in total
  3 in total

1.  Reply to Yoshida: Liver cancer stem cells: Identification and lipid metabolic reprogramming.

Authors:  Xian-Yang Qin; Naoshi Dohmae; Soichi Kojima
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

Review 2.  Emerging roles of Myc in stem cell biology and novel tumor therapies.

Authors:  Go J Yoshida
Journal:  J Exp Clin Cancer Res       Date:  2018-07-27

Review 3.  Beyond the Warburg Effect: N-Myc Contributes to Metabolic Reprogramming in Cancer Cells.

Authors:  Go J Yoshida
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.